Matches in SemOpenAlex for { <https://semopenalex.org/work/W2223723980> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2223723980 endingPage "7301" @default.
- W2223723980 startingPage "7301" @default.
- W2223723980 abstract "7301 Background: Irinotecan and etoposide are active drugs in small cell lung cancer (SCLC). We aimed to assess the activity of irinotecan plus oral etoposide (IRET) combination in patients with small cell lung cancer. Here we present the very impressive preliminary results of the trial. Methods: Patients with SCLC who were resistant to previous treatments or relapsed within 3 months of the completion of treatment constituted the study group. Treatment schedule consisted of irinotecan 80 mg/m2 on days 1 and 8, and oral etoposide 50 mg/day for 20 days, repeated every 30 days. Treatment was continued until disease progression or further 2 cycles after disease stabilization. Results: To date a total of 20 consecutive patients (16 male, 4 female) with a median age of 59 years (range: 41–71) have been included. While two patients had locally advanced disease the others had distant metastases (7 cerebral, 7 liver, 4 bone, 4 surrenal and 1 bone marrow). The results of initial 17 patients are currently available within a median follow-up time of 9 months (range: 3–18 months). Seven patients were given the current schedule as a second line treatment, 8 third line and 2 fourth line. There were 10 objective responses (OR) (55.6%) with one complete response. Median progression-free survival time was 7 (95% CI: 4 - 9) months. Median overall survival time has not been reached yet. Six-month survival rate was 60.4%. The toxicity was acceptable with grade 3 neutropenia in 2 patients and grade 2 diarrhea in 2 patients. However, one patient with bone marrow metastases died of febrile neutropenia following the first cycle. Conclusions: Irinotecan plus oral etoposide combination is a well-tolerated and active regimen in heavily pre-treated small cell lung cancer patients and the current schedule merits a phase III trial. No significant financial relationships to disclose." @default.
- W2223723980 created "2016-06-24" @default.
- W2223723980 creator A5007329398 @default.
- W2223723980 creator A5015934736 @default.
- W2223723980 creator A5028874448 @default.
- W2223723980 creator A5033348156 @default.
- W2223723980 creator A5033798750 @default.
- W2223723980 creator A5060378855 @default.
- W2223723980 creator A5061917722 @default.
- W2223723980 creator A5090666502 @default.
- W2223723980 date "2005-06-01" @default.
- W2223723980 modified "2023-09-25" @default.
- W2223723980 title "Irinotecan plus oral etoposide (IRET) combination is an highly active and promising treatment in heavily pre-treated small cell lung cancer patients" @default.
- W2223723980 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.7301" @default.
- W2223723980 hasPublicationYear "2005" @default.
- W2223723980 type Work @default.
- W2223723980 sameAs 2223723980 @default.
- W2223723980 citedByCount "0" @default.
- W2223723980 crossrefType "journal-article" @default.
- W2223723980 hasAuthorship W2223723980A5007329398 @default.
- W2223723980 hasAuthorship W2223723980A5015934736 @default.
- W2223723980 hasAuthorship W2223723980A5028874448 @default.
- W2223723980 hasAuthorship W2223723980A5033348156 @default.
- W2223723980 hasAuthorship W2223723980A5033798750 @default.
- W2223723980 hasAuthorship W2223723980A5060378855 @default.
- W2223723980 hasAuthorship W2223723980A5061917722 @default.
- W2223723980 hasAuthorship W2223723980A5090666502 @default.
- W2223723980 hasConcept C121608353 @default.
- W2223723980 hasConcept C126322002 @default.
- W2223723980 hasConcept C141071460 @default.
- W2223723980 hasConcept C2776256026 @default.
- W2223723980 hasConcept C2776581026 @default.
- W2223723980 hasConcept C2776694085 @default.
- W2223723980 hasConcept C2777063308 @default.
- W2223723980 hasConcept C2778119113 @default.
- W2223723980 hasConcept C2780259306 @default.
- W2223723980 hasConcept C526805850 @default.
- W2223723980 hasConcept C71924100 @default.
- W2223723980 hasConcept C90924648 @default.
- W2223723980 hasConceptScore W2223723980C121608353 @default.
- W2223723980 hasConceptScore W2223723980C126322002 @default.
- W2223723980 hasConceptScore W2223723980C141071460 @default.
- W2223723980 hasConceptScore W2223723980C2776256026 @default.
- W2223723980 hasConceptScore W2223723980C2776581026 @default.
- W2223723980 hasConceptScore W2223723980C2776694085 @default.
- W2223723980 hasConceptScore W2223723980C2777063308 @default.
- W2223723980 hasConceptScore W2223723980C2778119113 @default.
- W2223723980 hasConceptScore W2223723980C2780259306 @default.
- W2223723980 hasConceptScore W2223723980C526805850 @default.
- W2223723980 hasConceptScore W2223723980C71924100 @default.
- W2223723980 hasConceptScore W2223723980C90924648 @default.
- W2223723980 hasIssue "16_suppl" @default.
- W2223723980 hasLocation W22237239801 @default.
- W2223723980 hasOpenAccess W2223723980 @default.
- W2223723980 hasPrimaryLocation W22237239801 @default.
- W2223723980 hasRelatedWork W1976646314 @default.
- W2223723980 hasRelatedWork W2018507611 @default.
- W2223723980 hasRelatedWork W2054165374 @default.
- W2223723980 hasRelatedWork W2082769284 @default.
- W2223723980 hasRelatedWork W2084101102 @default.
- W2223723980 hasRelatedWork W2105544590 @default.
- W2223723980 hasRelatedWork W2166655722 @default.
- W2223723980 hasRelatedWork W2170402962 @default.
- W2223723980 hasRelatedWork W2404962907 @default.
- W2223723980 hasRelatedWork W3000727952 @default.
- W2223723980 hasVolume "23" @default.
- W2223723980 isParatext "false" @default.
- W2223723980 isRetracted "false" @default.
- W2223723980 magId "2223723980" @default.
- W2223723980 workType "article" @default.